Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.
- Trial name
- NCT01119950
- Testing
- NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 388 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5.
- Trial name
- STRENGTH (NCT06678191)
- Testing
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- Where
- 45 sites in Hungary
- Volunteers
- 800 people
- Sponsor
- Chiesi Hungary Ltd.
Airway Obstruction, Asthma
Effects of Combined Respiratory Muscle Training and Steam Inhalation
The purpose of this investigation is to obtain more information on the efficacy and safety of respiratory training methods with WellO2 in patients with asthma and COPD.
- Conditions
- Airway Obstruction, Asthma, COPD
- Trial name
- NCT04584398
- Testing
- Respiratory muscle training with steam inhalation
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- WellO2 Oy
Chronic Obstructive Pulmonary Disease, Asthma
Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom
The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.
- Trial name
- NCT01715493
- Testing
- lysozyme 90 mg
- Where
- Japan
- Volunteers
- 48 people
- Sponsor
- Eisai Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT06547333
- Testing
- CM310
- Volunteers
- 884 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease
An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects
The purpose of this study is to monitor adherence to a clothing-attached breathing monitor, respiratory patterns, and activity levels in COPD patients, and correlate those respiratory patterns and activity levels with…
- Trial name
- NCT03745547
- Testing
- Adherence to wearing a Spire wearable health monitor
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Spire, Inc.
Bronchitis, Chronic, Pulmonary Disease, Chronic Obstructive
Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis
The purpose of this study is to evaluate the mucolytic activity of Tacholiquine® compared to saline (0.9%) in chronic bronchitis patients.
- Trial name
- Tacho-COPD (NCT02515799)
- Testing
- Tacholiquine
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- bene-Arzneimittel GmbH
Chronic Obstructive Pulmonary Disease
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
The purpose of this study is to evaluate the dose-response relationship of different doses of CHF6001 and to identify the optimal dose (s) in terms of benefit/risk ratio for further development in the target patient population.
- Trial name
- PIONEER (NCT02986321)
- Testing
- CHF6001, Budesonide
- Volunteers
- 1,130 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD, Asthma
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation
- Trial name
- NCT02490358
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
- Trial name
- NCT00274508
- Testing
- tiotropium bromide
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Lung Disease
A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a phase 1b/2a, open-label, non-randomized, observation of 125 adults, with moderate to severe chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells).
- Trial name
- SORT-COPD II (NCT07871890)
- Testing
- Stem cells
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- SMSbiotech
Pulmonary Disease, Chronic Obstructive
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD.
- Trial name
- NCT00500318
- Testing
- Aclidinium Bromide
- Where
- 52 sites in United States, Canada
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- AC4115321 (NCT01372410)
- Testing
- GSK573719, Tiotropium
- Where
- 13 sites in United States
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Sarcopenia, COPD
Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease
This trial is a prospective multi-center study. The purpose of this study is to evaluate the effect of dietary supplement combined with supervised exercised on the physical performance, body composition and lung function among…
- Conditions
- Sarcopenia, COPD, ILD
- Trial name
- NCT05926713
- Testing
- Sarcojoint®, supervised exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Orient Europharma Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one…
- Trial name
- NCT02546700
- Testing
- Lebrikizumab
- Where
- 63 sites in United States, Argentina and 7 more
- Volunteers
- 309 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg once daily) and Atrovent® MDI (2 puffs of 20µg q.i.d.) among Filipino patients with COPD
- Trial name
- NCT02172469
- Testing
- Tiotropium inhalation powder capsule, Ipratropium Bromide Metered Dose Inhaler
- Volunteers
- 215 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of…
- Trial name
- NCT00206154
- Testing
- Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
- Where
- 212 sites in United States, Czechia and 3 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Bronchitis, COPD
Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD
This study aims to examine the clinical efficacy of synatura in patients with chronic bronchitis type COPD in Korea.
- Trial name
- NCT03623282
- Testing
- Synatura® 15 mL
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
The aim of this study is to describe patient preferences on budesonide/formoterol fix dose combination for the treatment of their COPD, and to find those factors more strongly associated to a better attitude to medication.
- Trial name
- NCT01646424
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
COPD, Home Care
FiO2 in Chronic Obstructive Pulmonary Disease (COPD) Patient Normobaric O2 Versus NIV
The purpose of this study is to compare pharyngeal FiO2 in day time with nasal normobaric O2 with inhaled FiO2 in the night time with home care ventilator NIV at the same O2 flow.
- Conditions
- COPD, Home Care, Oxygen Therapy
- Trial name
- NIVLEAKS (NCT02599246)
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Breas Medical S.A.R.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.